Filtered By:
Condition: Heart Attack
Cancer: Cancer
This page shows you your search results in order of relevance. This is page number 17.
Order by Relevance | Date
Total 1416 results found since Jan 2013.
Diabetes drug pioglitazone could get personal: Neither panacea, nor peril
When I was in training, one of my beloved mentors declared, “I never use a drug until it’s been on the market for 20 years.” I was young enough then that I couldn’t fathom being a doctor for 20 years, let alone waiting two decades to use a new drug. As my career has progressed, I’ve seen many new drugs released to the market. Some of them are truly miraculous, bringing people longer, healthier, and more productive lives. Many of them have not withstood the test of time. More than a few have even been taken off the market. Even though the Food and Drug Administration diligently reviews each new medicine before it...
Source: New Harvard Health Information - May 5, 2016 Category: Consumer Health News Authors: Lori Wiviott Tishler, MD, MPH Tags: Diabetes Drugs and Supplements pioglitazone thiazolidinediones Source Type: news
Pre-treatment clinical assessment in head and neck cancer: United Kingdom National Multidisciplinary Guidelines.
Authors: Robson A, Sturman J, Williamson P, Conboy P, Penney S, Wood H
Abstract
This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. This paper provides recommendations on the pre-treatment clinical assessment of patients presenting with head and neck cancer. Recommendations • Comorbidity data should be collected as it is important in the analysis of survival, quality of life and functional outcomes after treatment as well as for comparing results of different treatment regimens and different centres. (R) • Patients with hypertens...
Source: Journal of Laryngology and Otology - November 15, 2016 Category: ENT & OMF Tags: J Laryngol Otol Source Type: research
Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease Proteomics and Protein Markers
CONCLUSIONS:
In stable CHD, GDF-15 was independently associated with CV, non-CV, and cancer mortality, as well as with MI and stroke. When also adjusting for other prognostic biomarkers, the associations to all fatal and nonfatal events were maintained except for MI. Information on GDF-15, therefore, might be helpful when assessing the risk of adverse outcomes in patients with stable CHD. ClinicalTrials.gov Identifier: NCT00799903
Source: Clinical Chemistry - December 29, 2016 Category: Chemistry Authors: Hagstrom, E., Held, C., Stewart, R. A. H., Aylward, P. E., Budaj, A., Cannon, C. P., Koenig, W., Krug-Gourley, S., Mohler, E. R., Steg, P. G., Tarka, E., Ostlund, O., White, H. D., Siegbahn, A., Wallentin, L., on behalf of the STABILITY Investigators Tags: Proteomics and Protein Markers Source Type: research
Long-term daily drinking linked to stiffening of the arteries in men
Conclusion
This prospective cohort study aimed to look at the relationship between long-term alcohol patterns and stiffness of the arteries as a potential indicator of cardiovascular health.
The researchers found men who were stable heavy drinkers had stiffer arteries compared with stable moderate drinkers.
Male former drinkers also had increasingly stiffer arteries over the following four to five years compared with consistent moderate drinkers. There were no significant findings seen for women at all.
But this study does have limitations:
This type of study is not able to prove drinking causes stiffness of the arter...
Source: NHS News Feed - February 21, 2017 Category: Consumer Health News Tags: Heart/lungs Food/diet Source Type: news
Anti-inflammatory drug may help prevent heart attacks
Conclusion
This well-conducted study shows promising signs that canakinumab may reduce the risk of future heart attacks and other cardiovascular events in people who've had them in the past.
But before any changes are made to the current licensing of this drug, further research is needed to confirm the beneficial effects and the optimal dose.
Most importantly, researchers will need to focus on the observation that the drug lowered white blood cell counts and increased the risk of fatal infection.
They estimated around 1 in every 300 people taking canakinumab would die of a fatal infection. This number, while low, is sti...
Source: NHS News Feed - August 30, 2017 Category: Consumer Health News Tags: Heart/lungs Source Type: news
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
Publication date: Available online 6 December 2017 Source:The Lancet Diabetes & Endocrinology Author(s): M Angelyn Bethel, Rishi A Patel, Peter Merrill, Yuliya Lokhnygina, John B Buse, Robert J Mentz, Neha J Pagidipati, Juliana C Chan, Stephanie M Gustavson, Nayyar Iqbal, Aldo P Maggioni, Peter Öhman, Neil R Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F Hernandez, Rury R Holman Background Glucagon-like peptide-1 (GLP-1) receptor agonists are effective glucose-lowering drugs. Findings from cardiovascular outcome trials showed cardiovascular safety of GLP-1 receptor agonists, but results for cardiovascular...
Source: The Lancet Diabetes and Endocrinology - December 6, 2017 Category: Endocrinology Source Type: research
Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis Pharmacology
Conclusions—
Across trials of cardiovascular and cerebrovascular disease, extended-duration clopidogrel on a background of aspirin has no overall effect on mortality or cancer but does reduce rates of myocardial infarction and stroke and increase rates of bleeding. These findings emphasize the need for selective use of extended clopidogrel therapy in patients in whom the risks of ischemia are not fully counterbalanced by the risks of bleeding.
Source: Circulation: Cardiovascular Interventions - January 8, 2018 Category: Cardiology Authors: Elmariah, S., Doros, G., Benavente, O. R., Bhatt, D. L., Connolly, S. J., Yusuf, S., Steinhubl, S. R., Liu, Y., Hsieh, W.-H., Yeh, R. W., Mauri, L. Tags: Pharmacology, Meta Analysis, Mortality/Survival Source Type: research
Atrial Fibrillation, Clinical Profile and Adherence to Guidelines
Conclusion: Discordance between guidelines and practice was found regarding prescription of OACs and maintenance of optimal anticoagulation for stroke prevention in our population. Optimal anticoagulation needs to be emphasized on both patients as well as physicians to prevent strokes and achieve better outcomes.Keywords:CHADS2 score,International normalized ratio,Oral Anticoagulants,Valvular heart disease.View:PDF (138.96 KB)Click here to download the PDF file.‹ Breast Cancer and the Heart: Burden on the ChestAssociation between Myocardial Infarction and Dermatoglyphics: A Cross-Sectional Study ›
Source: Journal of Cardiovascular Disease Research - March 8, 2018 Category: Cardiology Authors: yunus Source Type: research
Current Tobacco Smoking, Quit Attempts, and Knowledge About Smoking Risks Among Persons Aged ≥15 Years - Global Adult Tobacco Survey, 28 Countries, 2008-2016.
Abstract
Each year, tobacco use causes approximately 7 million deaths worldwide, including approximately 6 million among tobacco users and an estimated 890,000 among nonsmokers exposed to secondhand smoke (1). Tobacco use is a leading preventable cause of disease globally and has been determined to cause adverse health outcomes such as coronary heart disease, stroke, and multiple types of cancer, including lung cancer (2-4). Approximately 80% of the world's 1.1 billion tobacco smokers reside in low- and middle-income countries (4). Some persons do not fully understand the health risks associated with tobacco smoki...
Source: MMWR Morb Mortal Wkl... - September 28, 2018 Category: Epidemiology Authors: Ahluwalia IB, Smith T, Arrazola RA, Palipudi KM, Garcia de Quevedo I, Prasad VM, Commar A, Schotte K, Garwood PD, Armour BS Tags: MMWR Morb Mortal Wkly Rep Source Type: research
Fish Oil and Vitamin D Supplements May Not Help Prevent Heart Attacks and Cancer, Study Says
There’s good evidence that fish oil supplements may lower the risk of second heart events — like a heart attack or stroke — in people with heart disease, but few rigorous studies have investigated whether the supplement can help people to lower their risk of having a heart event in the first place. And while some data suggests that people with lower levels of vitamin D tend to have higher rates of heart disease and cancer, the evidence isn’t solid.
Now, a new study published in the New England Journal of Medicine and presented at the annual meeting of the American Heart Association offers more findi...
Source: TIME: Health - November 10, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Drugs Source Type: news
New Studies Give Mixed Results About Taking Fish Oil and Vitamin D
(CHICAGO) — Taking fish oil or vitamin D? Big studies give long-awaited answers on who does and does not benefit from these popular nutrients.
Fish oil taken by healthy people, at a dose found in many supplements, showed no clear ability to lower heart or cancer risks. Same for vitamin D.
But higher amounts of a purified, prescription fish oil slashed heart problems and heart-related deaths among people with high triglycerides, a type of fat in the blood, and other risks for heart disease. Doctors cheered the results and said they could suggest a new treatment option for hundreds of thousands of patients like these.
...
Source: TIME: Health - November 10, 2018 Category: Consumer Health News Authors: MARILYNN MARCHIONE / AP Tags: Uncategorized onetime Supplements Source Type: news
Death after diagnosis of noncommunicable disease comorbid conditions, stratified by injection drug use
Conclusion:
Persons with a history of injection drug use and non-IDU had strikingly similar risk and hazard of mortality after several major NCD diagnoses. Mortality after cancer diagnosis in this cohort was higher for persons with a history of IDU than those without; this may be because of being diagnosed with a different mix of specific sites and stages of cancers.
Source: AIDS - December 20, 2018 Category: Infectious Diseases Tags: Epidemiology and Social Source Type: research
Study: Drinking Tea May Help You Live Longer, Especially If It ’ s Green
This study strengthens the body of evidence that habitual tea drinking is associated with lower rates of atherosclerotic cardiovascular disease, though it cannot prove that it’s definitely the tea that’s responsible,” Dr. Jenna Macciochi, a lecturer in immunology at the University of Sussex, told the SMC.
However, she noted that “a body of evidence in nutrition suggests that whole diet patterns are more informative of diet-disease relationships than any isolated food or nutrient.”
Dr. Duane Mellor, a registered dietitian and senior teaching fellow at Aston Medical School, Aston University, sai...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 10, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Syndicated CBSN Boston CNN Green Tea Source Type: news
Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.
CONCLUSIONS: In this population-based study, aromatase inhibitors were associated with increased risks of heart failure and cardiovascular mortality compared with tamoxifen. There were also trends toward increased risks, although nonsignificant, of myocardial infarction and ischemic stroke. The increased risk of cardiovascular events associated with aromatase inhibitors should be balanced with their favorable clinical benefits compared with tamoxifen.
PMID: 32065766 [PubMed - in process]
Source: Circulation - February 17, 2020 Category: Cardiology Authors: Khosrow-Khavar F, Filion KB, Bouganim N, Suissa S, Azoulay L Tags: Circulation Source Type: research
Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormones
(American Heart Association) Patients with breast and prostate cancers who are treated with hormonal therapies have an increased risk of heart attack and/or stroke as they age.The increased likelihood of a heart attack or stroke is greater in patients who already have two or more cardiovascular risk factors such as high blood pressure, high cholesterol, obesity, smoking or a family history of heart disease or stroke.The longer the duration of hormonal therapy, the higher the risk of cardiovascular disease.
Source: EurekAlert! - Medicine and Health - April 26, 2021 Category: International Medicine & Public Health Source Type: news
